Equities research analysts at Stephens started coverage on shares of Humana (NYSE:HUM) in a research report issued to clients and investors on Monday, The Fly reports. The brokerage set an “overweight” rating on the insurance provider’s stock.

A number of other analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 price target on the stock in a research report on Thursday, October 4th. JPMorgan Chase & Co. upgraded shares of Humana from a “neutral” rating to an “overweight” rating and set a $283.00 price target on the stock in a research report on Thursday, December 20th. Royal Bank of Canada increased their price target on shares of Humana from $318.00 to $349.00 and gave the company a “sector perform” rating in a research report on Thursday, November 8th. SunTrust Banks increased their price target on shares of Humana to $380.00 and gave the company a “hold” rating in a research report on Wednesday, September 19th. Finally, BMO Capital Markets set a $390.00 price target on shares of Humana and gave the company a “buy” rating in a research report on Thursday, November 8th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $349.53.

Shares of NYSE HUM opened at $283.47 on Monday. The stock has a market capitalization of $37.90 billion, a PE ratio of 24.21, a price-to-earnings-growth ratio of 1.08 and a beta of 1.09. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.68 and a current ratio of 1.68. Humana has a 1 year low of $260.00 and a 1 year high of $355.88.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, beating analysts’ consensus estimates of $4.29 by $0.29. The business had revenue of $14.21 billion for the quarter, compared to the consensus estimate of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same period last year, the company posted $3.39 EPS. Analysts expect that Humana will post 14.43 EPS for the current year.

In related news, insider Roy A. Beveridge sold 4,622 shares of the firm’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the transaction, the insider now directly owns 10,621 shares of the company’s stock, valued at $3,622,398.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David A. Jr/Ky Jones sold 400 shares of the firm’s stock in a transaction on Saturday, March 16th. The shares were sold at an average price of $86.32, for a total transaction of $34,528.00. The disclosure for this sale can be found here. Insiders have sold a total of 9,078 shares of company stock worth $2,570,350 over the last 90 days. Corporate insiders own 0.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in HUM. Envestnet Asset Management Inc. boosted its position in Humana by 13.4% during the second quarter. Envestnet Asset Management Inc. now owns 4,440 shares of the insurance provider’s stock worth $1,321,000 after purchasing an additional 525 shares during the period. Raymond James & Associates boosted its position in Humana by 35.1% during the second quarter. Raymond James & Associates now owns 37,765 shares of the insurance provider’s stock worth $11,240,000 after purchasing an additional 9,820 shares during the period. First Republic Investment Management Inc. boosted its position in Humana by 31.1% during the second quarter. First Republic Investment Management Inc. now owns 3,129 shares of the insurance provider’s stock worth $932,000 after purchasing an additional 743 shares during the period. Cubist Systematic Strategies LLC boosted its position in Humana by 12.4% during the second quarter. Cubist Systematic Strategies LLC now owns 2,712 shares of the insurance provider’s stock worth $807,000 after purchasing an additional 300 shares during the period. Finally, Marshall Wace LLP boosted its position in Humana by 195.3% during the second quarter. Marshall Wace LLP now owns 19,329 shares of the insurance provider’s stock worth $5,753,000 after purchasing an additional 12,784 shares during the period. 92.69% of the stock is owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: Why is insider trading harmful?

The Fly

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.